MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Lapatinib In The Treatment Of Breast Cancer

Back to breast cancer blog Blogs list Cancer blog  


Subscribe To Breast Cancer Blog RSS Feed  RSS content feed What is RSS feed?

Lapatinib In The Treatment Of Breast Cancer

Lapatinib In The Treatment Of Breast Cancer
Based on the unanimous recommendation of an Independent Data Monitoring Committee (IDMC), GlaxoSmithKline announced that it has halted enrollment in its Phase III clinical trial evaluating the combination of Tykerb (lapatinib ditosylate) and capecitabine (Xeloda(R)) versus capecitabine alone.

The trial evaluated women with refractory advanced or metastatic breast cancer who have documented ErbB2 (HER2) overexpression and whose disease progressed following treatment with trastuzumab (Herceptin(R)) as well as other cancer therapies. A pre-planned interim analysis of 321 patients in the study yielded statistically significant results, exceeding the primary endpoint.

According to the study protocol, the pre-planned interim analysis was reviewed by the IDMC, which is comprised of medical oncology experts and a statistician. The IDMC unanimously recommended halting enrollment in the study because it exceeded its primary endpoint of time to disease progression, or TTP, for women receiving the combination of Tykerb and capecitabine. The IDMC made their recommendation based on pre-specified stopping rules outlined in their charter. All women currently enrolled in the trial will continue to be followed and those who are receiving capecitabine alone will be offered the option of switching to the combination therapy of capecitabine and Tykerb in consultation with their physician.



Posted by: Janet    Source




Did you know?
Based on the unanimous recommendation of an Independent Data Monitoring Committee (IDMC), GlaxoSmithKline announced that it has halted enrollment in its Phase III clinical trial evaluating the combination of Tykerb (lapatinib ditosylate) and capecitabine (Xeloda(R)) versus capecitabine alone.

Medicineworld.org: Lapatinib In The Treatment Of Breast Cancer

BREAST CANCER MAIN| Home| Breast cancer news| Common terms| Breast cancer treatment| Breast cancer treatment by stage| Mammogram and breast cancer screening| Surgical treatment of breast cancer| Chemotherapy of breast cancer| Chemo drugs used in breast cancer| Doxorubicin| Cyclophosphamide| Methotrexate| Hormonal therapy of breast cancer| Radiation therapy of breast cancer| Monoclonal therapy| High dose chemotherapy for breast cancer| Recurrent breast cancer| Bisphosphonates and breast cancer| Pregnancy and breast cancer| Risk factors for breast cancer| Risk details| My risk| Comprehensive breast cancer information| Breast cancer statistics| African Americans and breast cancer| Ashkenazi and breast cancer| Asians| Hispanic| Men| Native Americans| Older women and breast cancer| Younger women| Pregnant women and breast cancer| BRCA|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.